Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (251-260 of 347) with videos related to

Pageof 35
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
International Journal of Cancer|May 14, 2020
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroupShiyu Jiang, Yan Qin, Hongxin Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2020
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I studyJianliang Yang, Lihou Dong, Sheng Yang, et al.
Thoracic Cancer|January 23, 2019
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303Xiaoyan Si, Li Zhang, Hanping Wang, et al.
Cancer Communications (London, England)|June 22, 2019
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapyMing Zhou, Xiaoyuan Chen, Hong Zhang, et al.
The Lancet Regional Health. Western Pacific|April 25, 2022
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective studyYuankai Shi, Xin Zhang, Gang Wu, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 19, 2014
Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Mei Dong, et al.
Hematology (Amsterdam, Netherlands)|April 15, 2016
Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomasBo Jia, Shaoxuan Hu, Jianliang Yang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 13, 2018
[China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)]Qinghua Zhou, Yaguang Fan, Ying Wang, et al.
Journal of Cellular and Molecular Medicine|August 9, 2019
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancerPuyuan Xing, Xiaohong Han, Sha Wang, et al.
Pageof 35

Showing results (251-260 of 347) with videos related to

Sort By:
Pageof 35
Lung Cancer (Amsterdam, Netherlands)|March 6, 2022
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitorsLin Lin, Hongming Pan, Xingya Li, et al.
International Journal of Cancer|May 14, 2020
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroupShiyu Jiang, Yan Qin, Hongxin Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2020
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I studyJianliang Yang, Lihou Dong, Sheng Yang, et al.
Thoracic Cancer|January 23, 2019
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303Xiaoyan Si, Li Zhang, Hanping Wang, et al.
Cancer Communications (London, England)|June 22, 2019
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapyMing Zhou, Xiaoyuan Chen, Hong Zhang, et al.
The Lancet Regional Health. Western Pacific|April 25, 2022
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective studyYuankai Shi, Xin Zhang, Gang Wu, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 19, 2014
Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Mei Dong, et al.
Hematology (Amsterdam, Netherlands)|April 15, 2016
Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomasBo Jia, Shaoxuan Hu, Jianliang Yang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 13, 2018
[China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)]Qinghua Zhou, Yaguang Fan, Ying Wang, et al.
Journal of Cellular and Molecular Medicine|August 9, 2019
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancerPuyuan Xing, Xiaohong Han, Sha Wang, et al.
Pageof 35